10 Years Treating Bifurcations: Have We Made Progress?

Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history.  This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,<a href="https://solaci.org/en/2021/10/26/10-years-treating-bifurcations-have-we-made-progress/" title="Read more" >...</a>

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this trial comes along directing us back to basics.  In patients with symptomatic aortic stenosis, peaking mortality will clearly justify intervention. But what is the case when there are no symptoms? According to this recent analysis published in JAMA,<a href="https://solaci.org/en/2021/10/08/more-keys-to-define-moderate-aortic-stenosis/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

The FDA Approves a Third Device in the TAVR Race

The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three options available in clinical practice for transcatheter aortic valve replacement (TAVR) in the United States. For the time being, its indication will have some restrictions: for example, it can only be used in high-risk patients (unlike CoreValve and<a href="https://solaci.org/en/2021/10/06/the-fda-approves-a-third-device-in-the-tavr-race/" title="Read more" >...</a>

The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-<a href="https://solaci.org/en/2021/10/05/the-latest-scientific-articles-on-tavi-published-on-our-website/" title="Read more" >...</a>

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and<a href="https://solaci.org/en/2021/09/29/tavr-and-anticoagulation-direct-anticoagulant-agents-or-vitamin-k-inhibitors/" title="Read more" >...</a>

La revascularización incompleta se asocia a mortalidad en el TAVI

Thrombotic and Bleeding Risk after TAVR: Quick Tips to Stay Up to Date

Transcatheter aortic valve replacement (TAVR) is an increasingly frequent option for patients with severe aortic stenosis across the entire risk spectrum.  However, TAVR involves bleeding and thrombosis risk and therefore calls for an optimal adjuvant treatment.  Any scheme is complex if we take into account most patients undergoing TAVR are generally elderly and have multiple<a href="https://solaci.org/en/2021/09/21/thrombotic-and-bleeding-risk-after-tavr-quick-tips-to-stay-up-to-date/" title="Read more" >...</a>

SAPIEN 3 Ultra: Lower Incidence of Paravalvular Regurgitation?

Paravalvular regurgitation after transcatheter aortic valve replacement (TAVR) have historically been associated with worse clinical outcomes. Even mild leaks have been shown to be harmful.  This study looked at a real-world experience with the transcatheter heart valve SAPIEN 3 Ultra in the US.  The SAPIEN 3 Ultra is a new generation balloon-expandable heart valve with<a href="https://solaci.org/en/2021/09/17/sapien-3-ultra-lower-incidence-of-paravalvular-regurgitation/" title="Read more" >...</a>

Access all contents of the 11th ProEducar Fellows Course

During the virtual SOLACI-CACI 2021 Congress, the 11th ProEducar Fellows Course—SOLACI’s traditional activity aimed at expanding knowledge and providing didactic tools for all interventional trainees in Latin America—was held. The course was a huge success: almost 1500 people accessed the Andreas Gruentzig Virtual Room where the activity took place. Furthermore, over 35 prestigious speakers from all<a href="https://solaci.org/en/2021/09/15/access-all-contents-of-the-11th-proeducar-fellows-course/" title="Read more" >...</a>

SOLACI-CACI 2021 | Day 1: Main Arena Auditorium

✔️ Day 1, SOLACI-CACI 2021 ✔️ Main Arena Auditorium 👨‍🏫 Program: 06:20 – TCT@SOLACI-CACI 2021 Session – “The Future of PCI” 01:33:19 – PCR@SOLACI-CACI 2021 Session 👉 How to manage Coronary Artery Disease in patients with Severe Aortic Stenosis eligible for TAVI? 👉 How to predict, how to avoid peri-procedural coronary obstruction during a TAVI<a href="https://solaci.org/en/2021/09/15/solaci-caci-2021-day-1-main-arena-auditorium/" title="Read more" >...</a>

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31